Literature DB >> 20926592

Limited utility of oral glucose tolerance test in biochemically active acromegaly.

Antônio Ribeiro-Oliveira1, Alexander T Faje, Ariel L Barkan.   

Abstract

CONTEXT: Measurement of GH after oral glucose tolerance test (OGTT) is used for the diagnosis and surveillance of acromegaly. However, there are major discrepancies between glucose-suppressed GH and plasma IGF1 as indices of biochemical activity of acromegaly in patients with relatively mild GH oversecretion. This study was aimed to assess the performance of OGTT in patients with acromegaly and variable GH outputs.
METHODS: Forty adults with newly diagnosed, untreated acromegaly (15 with GH >4.3 μg/l and 25 with GH <4.3 μg/l) and elevated IGF1 levels were studied. All underwent Q10 min for 24 h sampling for GH followed by an OGTT.
RESULTS: Postglucose nadir GH (GHn) correlated significantly to 24 h GHn, mean 24 h GH, and baseline GH (P<0.001 for all comparisons). GHn correlated significantly to IGF1 z-scores for the 'low' GH group and for the entire group (P<0.0001 for both comparisons), but not for the 'high' GH group. None of the patients with mean GH >4.3 μg/l had GHn below 1 μg/l. In contrast, 13 out of 25 patients (52%) with GH <4.3 μg/l showed GHn lower than 1 μg/l, and 7 of them (28%) had GHn lower than 0.4 μg/l. These groups did not differ significantly either for average or for maximal GH suppression in OGTT.
CONCLUSIONS: Our data show that suppressibility of GH by glucose in acromegaly is a function of the degree of GH hypersecretion and that OGTT has only limited diagnostic value in patients with biochemically active acromegaly but only mildly increased GH output.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926592     DOI: 10.1530/EJE-10-0744

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.

Authors:  Laura B Butz; Stephen E Sullivan; William F Chandler; Ariel L Barkan
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

Review 3.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

Review 4.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.

Authors:  Francesco M Minuto; Eugenia Resmini; Mara Boschetti; Alberto Rebora; Laura Fazzuoli; Marica Arvigo; Massimo Giusti; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 6.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

7.  Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas.

Authors:  Antônio Ribeiro-Oliveira; Marcelo Militão Abrantes; Ariel L Barkan
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

8.  Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.

Authors:  Giulia Carosi; Alessandra Mangone; Elisa Sala; Giulia Del Sindaco; Roberta Mungari; Arianna Cremaschi; Emanuele Ferrante; Maura Arosio; Giovanna Mantovani
Journal:  Eur J Endocrinol       Date:  2021-07-01       Impact factor: 6.664

9.  Clinical manifestations and diagnosis of acromegaly.

Authors:  Gloria Lugo; Lara Pena; Fernando Cordido
Journal:  Int J Endocrinol       Date:  2012-02-01       Impact factor: 3.257

10.  The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study.

Authors:  Maysam Alimohamadi; Vahid Ownagh; Leila Mahouzi; Afshin Ostovar; Kazem Abbassioun; Abbas Amirjmshidi
Journal:  Asian J Neurosurg       Date:  2014 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.